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obesity (body mass index 44). She had no personal or family history
of cancer. She had seen a dermatologist for bumps on the right vertex
scalp and labia majora, and onychomycosis on her left great toenail.
She was referred to Gynecology with presumed diagnosis of Bartholin's
cyst of right labia majora.
Upon examination, a 1 × 0.5 × 0.5 cm-sized, ﬁrm, superﬁcial, and
non-tender nodule was seen on the right posterior labia majora. SheVulva
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Prognosisinteractor 1 (INI1) (Fig. 1a–d). There was no lymphovascular invasion,1. Introduction
Epithelioid sarcoma (ES) is a malignant soft tissue tumor. It is
classiﬁed into distal or proximal types, based on its occurrence in the
upper and lower extremities or in the trunk and pubic regions, respec-
tively. Proximal-type epithelioid sarcoma (PES) of the vulva is an
exceedingly rare condition. There are limited reports of this condition
in the literature (Iavazzo et al., 2014; Kim et al., 2012; Patrizi et al.,
2013). This disease occurs most often in women of reproductive age,
and despite its low occurrence poses a signiﬁcant health issue for
women. Due to the rarity of this disease, the guidelines for its optimal
treatment are not well established.
We are reporting a case of epithelioid sarcoma in a 32 year-old
female treated with radical vulvectomy and reviewing the literature
with focus on its treatment in young reproductive aged women.2. Case report
A 32-year old African American female presented with a palpable
nodule in the posterior portion of the right labia majora for 3 months.
She was gravida 5 and para 2 and reported no previous gynecologicic Oncology, Department of
Medicine, Woodruff Memorial
22, United States.
a).
. This is an open access article underdenied itching or irritation over the lesion. Vulvar biopsy was taken
from the lesion, and pathology revealed epithelioid sarcoma with high
mitotic feature extending to deep and lateral edges of excisional biopsy
specimen. The tumor stained positive for AE1/AE3 and smooth muscle
actin (SMA), and the stain for both S-100 and caldesmon was negative.
Themajority of tumor cells showed the absence of staining for integrase
and positron emission tomography–computed tomography (PET–CT)
did not demonstrate distant metastasis.
We treated the patient with radical hemivulvectomy. Final patholo-
gy of radical vulvectomy specimen demonstrated 5 mm sized remnant
tumor with superﬁcial invasion (less than 1 mm). The margins of
excision were negative.
The case was then reviewed at institutional tumor board and
consensus reached after reviewing the pathology and imaging was to
follow patient with close surveillance. Secondary to the small size,
superﬁcial invasion, lack of lymphovascular space invasion and no
evidence of metastatic disease on imaging, inguinal lymphadenectomy
was not considered necessary. Patient has since then been seen every
three months and is currently well, with no evidence of disease nine
months postoperatively.3. Discussion
ES is a malignant soft tissue tumor, which was established as a
distinct disease by Enzinger in 1970. The ﬁrst case of PES of the vulva
was described by Pier et al. in 1972 (Piver et al., 1972). PES of the
vulva often occurs in the labia majora of young women, and frequently
misdiagnosed as benign lesion such as Bartholin's cyst, lipoma, or geni-
tal warts. Our patient was also referred to our general gynecologic de-
partment for Bartholin's cyst management. Due to its benign
appearance as a painless subcutaneous nodule, diagnosis and treatment
can often be delayed signiﬁcantly (Moore et al., 2002; Ulutin et al.,
2003).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (a) H&E, ×400, (b) positive staining for AE1/AE3, ×400, (c) positive staining for SMA,×400, (d) Tumor cells stainingnegative for the INI1 compared to stromal cells staining positive,
×400.
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large polygonal cells with deeply acidophilic cytoplasm. It bears a
resemblance to epithelioid or squamous cells, which makes diagnosis
of PES challenging. The diagnosis can only be conﬁrmed with immuno-
chemical staining, as lack of staining for INI1 protein is one of the
characteristic ﬁndings (Kim et al., 2012).
The ideal treatment of PES remains unclear. There is no treatment of
choice universally accepted for vulvar epithelioid sarcoma (Iavazzo
et al., 2014). However, the cornerstone of initialmanagement is surgical
excision with a wide margin (Bos et al., 1988). The role and choice of
adjuvant therapy also remain unclear owing to the rarity of disease.
However, review literature by Argenta et al. reported lower recurrence
rates in patients who had adjuvant radiation therapy (Argenta et al.,
2007). Based on the literature, adjuvant chemotherapy does not seem
to improve the outcome. However, due to the small number of cases
available, it remains as an option (Altundag et al., 2004; Moore et al.,
2002).
Because optimal management is not well established, our under-
standing of genetic pathways involved in the tumorigenesis of ES and
developing target therapy might provide alternative therapeutic
options. SMARCB1/IN1 gene is located at 22q11 and acts as a tumor
suppressor gene. Previous studies found that inactivation of SMARCB1/
IN1 played a crucial role in tumorigenesis of ES and immunochemistry
studies revealed that 85 to 93% of cases have inactivated SMARCB1/IN1
(Hornick et al., 2009; Noujaim et al., 2015). Loss of expression can
occur with various mechanisms such as biallelic deletion, single-allelic
deletion, point mutation, or epigenetic gene silencing. Target therapy
restoring SMARCB1/IN1 gene function could provide new therapy in ES.
The prognosis of ES is not favorable; the lack of symptoms belies its
aggressive nature with rapid tendency of metastasis and highrecurrence rate. According to previous studies, 38%–69% of patients
had recurrence (Halling et al., 1996; Iavazzo et al., 2014; Ross et al.,
1997). Ivasazzo et al. reviewed 28 cases PES on the vulva speciﬁcally,
and reported 42% of recurrence rate with lung and lymph nodes as the
most common site of recurrence (Iavazzo et al., 2014).
We analyzed 37 cases of vulva PES from 32 studies (Table S1); the
mean age of patients was 38.6 ± 16.3 years (range, 17–84 years).
Sixteen patients among thirty-seven patients (43.2%) had recurrence
during follow-up, with a mean disease free survival time of 17.2 ±
25.2 months (range, 1–96 months). Ten among sixteen (62.5%)
recurrent patients died of disease.
Because overall peak incidence of ES is around 35 years of age and
the majority of vulva epithelioid sarcoma patients in previous reports
were aged 35 or less (20 out of 37 patients, 54.1%), we compared
these young patients with older patients in further analysis (Table S2).
Seven patients aged 35 or less (7 out of 20, 38.1%) and nine patients
aged 36 or more (9 out of 17, 40.5%) had recurrence. Patients who
were aged 35 years or less had 26.4 ± 33.5 months of disease free
survival time, whereas patients aged 36 years or more had 10.0 ±
14.7 months of disease free survival time. Three out of seven recurrent
patients aged 35 or less (42.9%) died of disease while seven out of
nine recurrent patients aged 36 or more (77.8%) died of disease. The
mean time from recurrence to death is 15.2 ± 17.2 months in younger
patients and 5.6 ± 4.5 months in older patients. This analysis suggested
that younger patients might have better prognosis than older patients,
but there was no statistical signiﬁcance (P N 0.05).
As PES of the vulva often develops in reproductive aged women,
maintenance of pregnancy and/or fertility should be considered in
treating patients (Chiyoda et al., 2011; Moore et al., 2002; Rai et al.,
2009). However, the clinical behavior is unfortunately not different
33C.H. Han et al. / Gynecologic Oncology Reports 15 (2016) 31–33from that of other non-pregnant patients, and can lead to a dismal
outcome in an effort to avoid surgery during pregnancy (Moore et al.,
2002).
As seen with our analysis, a signiﬁcant amount of patients (62.5%)
will die of disease if they have recurrence. Since it seems only an early
diagnosis with deﬁnite surgical treatment can improve prognosis,
physicians should have high suspicions in diagnosing this using prompt
biopsy, especially in young women for a potentially better prognosis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gore.2016.01.001.
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